Clinical trial
A Phase Ⅰb/Ⅱ, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-10380 in Chinese Adults With Schizophrenia.
NCT05964790 is registered in ClinicalTrials.gov with Jiangsu Hansoh Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase Ⅰb/Ⅱ, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-10380 in Chinese Adults With Schizophrenia.
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- July 30, 2023
- Completion date
- December 30, 2024
- Enrollment
- 112 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.